SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

Take-private speculation is the dominant topic, centered on Irth Capitals reported bid and a major U.S. franchisee joining the effort; traders are debating whether a deal will materialize, with no confirmed agreement in the discussion. The takeover hopes contrast with criticism of management and concern over weak sales, a dividend suspension, and the stocks steep decline.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

A sharp, news-unconfirmed XCN spike is driving attention, with traders reacting to a large candle and debating whether it marks a rebound or another brief pump-and-dump. Some are buying the dip and pointing to Bitcoins bounce, while skeptics say XCNs past spikes have quickly faded.

TOSHI

A burst of trading volume and a recent rebound have fueled talk of a technical breakout and a possible short squeeze in TOSHI, with many holders buying dips and anticipating a move through resistance. Others point to repeated failed breakouts, weak price action, and broader crypto-market softness; talk of an upcoming announcement or listing remains speculative.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

Crudes rally amid escalating Middle East tensions and fears of disrupted oil supplies is driving attention to UCO. Traders are divided between following the bullish momentum and positioning for a pullback, with some noting that geopolitical headlines could quickly shift the oil trade.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgens Phase 3 lung cancer results for IMDELLTRA plus AstraZenecas IMFINZI, which reduced the risk of death in first-line extensive-stage small cell lung cancer, are driving attention. Traders see the findings as a potential growth catalyst and debate how much they could expand the drugs commercial role alongside established products such as Repatha.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

XLE is drawing attention after reaching a new high as energy stocks outperform, with traders pointing to rising crude prices and supply risks tied to Middle East tensions and shipping disruptions. The conversation is broadly bullish on the breakout, though some traders warn the rally may be extended and question whether it can hold.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Mercks attention centers on Phase 3 results for its partnership with Moderna: the personalized cancer vaccine added to Keytruda reduced melanoma recurrence or death risk, drawing interest in the oncology platform and potential commercial upside. Traders debate whether the results justify further gains, given high expectations, unapproved status, and questions about manufacturing complexity and expansion beyond melanoma.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Updated Phase 3 VIKTORIA-1 breast-cancer subgroup data presented at ESMO is drawing attention, with traders highlighting stronger progression-free survival and response results for gedatolisib combinations. Reactions are mixed: some see the findings as compelling, while others note the data builds on previously released topline results and say CELC still needs to demonstrate commercial uptake and revenue.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

SHIB is drawing attention for choppy, largely sideways trading, with repeated technical posts describing consolidation and traders watching for a breakout. Holders are split between accumulating and anticipating a rebound, while skeptics point to weak momentum, limited utility, and the risk of further declines.

Anthropic

Anthropics anticipated blockbuster IPO is driving attention, with traders weighing rapid revenue growth against heavy compute commitments and reported losses. Some see a major AI-growth opportunity, while skeptics question whether the spending and intensifying competition can support the expected valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?

Execution of Pharma Tariffs Brings These ETFs Into Focus

Trump's 100% pharma tariff is reshaping the drug industry. Here's how the key pharma ETFs could be affected.

Healthcare ETFs Are Looking Up: Here's Why 

Healthcare ETFs are hitting 52-week highs as earnings improve, dealmaking accelerates, FDA approvals stay strong and investors seek defensive growth.

AstraZeneca's Rare Disease Setback Is A 'Clear Positive' For Omeros, Says This Analyst – A Look At Some Key Highlights 

Equity

H.C. Wainwright reiterated its ‘Buy’ rating on Omeros after AstraZeneca's Phase 3 setback in HSCT-TMA, saying that the outcome improves Yartemlea's competitive positioning.

ATAI Stock Downgraded Across Wall Street – Why Analysts Believe Buyout By Eli Lilly Capped Near-Term Upside

H.C. Wainwright and Berenberg became the latest firms to downgrade the stock following Eli Lilly's acquisition agreement.


ATAI Stock Soars On Eli Lilly’s $2.8B Buyout – Why Are CMPS Shares Rising Too?

Both ATAI and CMPS stocks were among the top trending on Stocktwits in pre-market trade.


SPDR Series Trust - State Street SPDR S&P Pharmaceuticals ETF

Neutral Sentiment

<ul class="summary-bullets"><li>AstraZeneca said Ultomiris failed to meet the primary endpoint of event-free survival through 26 weeks in a Phase 3 trial.</li><li>The company said that the study did not demonstrate a statistically significant improvement over placebo.</li><li>Despite the setback, AstraZeneca added it observed a trend toward treatment benefit and plans to continue discussions with health authorities regarding the adult indication.</li></ul>Omeros Corp. (OMER) shares drew investor attention on Monday after analysts at H.C. Wainwright said AstraZeneca's (AZN) late-stage setback for Ultomiris removes the biggest near-term competitive threat to Yartemlea, Omeros' FDA-approved treatment for transplant-associated thrombotic microangiopathy (TA-TMA).According to TheFly, the firm reiterated its ‘Buy’ rating on Omeros, calling AstraZeneca's Phase 3 miss in HSCT-TMA a "clear positive" that removes the key near-term competitive overhang for Yartemlea.<a href="https://stocktwits.com/symbol/OMER">OMER stock</a> was among the top trending tickers on Stocktwits at the time of writing. The stock jumped about 12% in morning trade.&nbsp;<h2 class="st-heading-2">AZN Trial Falls Short</h2>AstraZeneca said Ultomiris failed to meet the primary endpoint of event-free survival through 26 weeks in a Phase 3 trial evaluating the drug in adults and adolescents with TA-TMA.The study did not demonstrate a statistically significant improvement over placebo, the company said.Despite the setback, AstraZeneca added it observed a trend toward treatment benefit and plans to continue discussions with health authorities regarding the adult indication.The company also intends to move forward with regulatory filings for pediatric TA-TMA after a separate Phase 3 trial showed a statistically significant improvement in survival among children treated with Ultomiris.<h2 class="st-heading-2">Where OMER’s Yartemlea Stands</h2>Yartemlea (narsoplimab-wuug) is an FDA-approved inhibitor of the lectin pathway of complement for the treatment of transplant-associated thrombotic microangiopathy (TA-TMA) in adults and children ages 2 years and older.The rare complication can occur following hematopoietic stem cell transplants and has limited approved treatment options.H.C. Wainwright said AstraZeneca's setback improves Yartemlea's competitive positioning in TA-TMA by removing what it viewed as the most significant near-term rival.<h2 class="st-heading-2">HC Wainwright Keeps Focus On US Opportunity For OMER</h2>H.C. Wainwright previously argued that Omeros' long-term investment case hinged on Yartemlea's U.S. commercial potential. Last month, the firm lowered its price target to $33 from $40 after European regulators issued a negative opinion on the therapy, removing the EU opportunity from its valuation model and increasing its research and development spending assumptions.Even then, the firm said the regulatory setback was "not thesis-breaking," maintaining that a potential U.S. launch remained the primary driver of Omeros' value. The latest setback for AstraZeneca's Ultomiris further reinforces that view by easing competitive pressure in the U.S. market, according to the analyst.<h2 class="st-heading-2">What Retail Traders Think Of OMER Stock</h2>Retail sentiment on Stocktwits around Omeros trended in the ‘bullish’ territory at the time of writing.One user believes that Omeros needs transparency more than another bullish narrative.<stembedurl>https://stocktwits.com/lawson12/message/660078253</stembedurl><a href="https://stocktwits.com/symbol/OMER">OMER stock</a> is down 38% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/AZN">AZN stock</a> is down 7%. The State Street SPDR S&amp;P Pharmaceuticals ETF (XPH) is up 59% over the past 12 months, while the iShares Russell 2000 Value ETF (IWN) is up 34%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/default/equity/amzn-satellite-network-for-smartphones-what-leo-filing-reveals/cZZxl1FR76J">AMZN Is Building A Satellite Network For Smartphones — Here's What Its Latest Leo Filing Reveals</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Omeros Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Omeros Corp. (OMER) shares drew investor attention on Monday after analysts at H.C. Wainwright said AstraZeneca's (AZN) late-stage setback for Ultomiris removes the biggest near-term competitive threat to Yartemlea, Omeros' FDA-approved treatment for tran

AstraZeneca's Rare Disease Setback Is A 'Clear Positive' For Omeros, Says This Analyst – A Look At Some Key Highlights

AstraZeneca PLC

iShares Russell 2000 Value ETF

Omeros Corp

SPDR Pharmaceuticals ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

XPH SPDR Pharmaceuticals ETF

Fundamentals

Latest XPH News